Innovated steps changing the journey of diabetes
2nd - 4th February 2009, London, UK
The market for diabetes-related products is huge and continuing to grow. However, it is not the same market as it was just three years ago. New trends in care, new products, new approaches to long term complications, and changing public health priorities along with geographic variations are shifting the sands of opportunities in diabetes care. - Kalorama Information 2007
Type II or adult onset, diabetes, is the most widespread form of diabetes and with number of cases predicted by the International Diabetes Federation to be at 380 million by the year 2025 - Who will be the key players in the diabetes market? What kind of strategies are these companies using for their sales development and product lifecycle management? Will the oral anti-diabetics drugs and insulin still dominate the diabetes market and how will they compete with new innovated ideas being driven forward by the demanding diabetes market?
With diabetes expected to present one of the 21st century’s biggest medical challenges - What new research is being discovered that is linking diabetes with other medical conditions? The alarming increase of diabetes prevalence is projected to occur because of population aging, unhealthy diet, being over weight, obesity and sedentary lifestyle. The death rate in a diabetic person is 2 times higher than people without the disease.
With millions of pounds being invested in diabetes and as it stands currently without a cure... Who in the Diabetes market is fast tracking with innovated research and advancing formulations?
By attending visiongain’s 5th Annual Diabetes Conference, you will be a key participant in the journey of Diabetes. Our aim is to deliver, not only the best revolutionary technologies your company deserves, but provide you with the steps for advancement within the market.
5 Key reasons why you will not want to miss out:
1. Learn first-hand from the eminent industry and academic leaders in the diabetes market, and hear their analysis on productivity improvements
2. You will be provided with the results of robust research, and receive invaluable insights into the biopharmaceutical innovations that are leading the way forward
3. Stay ahead of the latest trends in pricing and reimbursement of the diabetes market
4. Be aware of what is driving the competitive edge in the diabetes market, and how you and your company will play a part
5. Take advantage of networking opportunities, which will only enhance your reputation as a key player in the diabetes journey of discovery
Key Themes:
The global diabetes market has seen a high level of innovation, particularly in non-invasive methods of insulin delivery, including inhalable, oral and patch technology. These non-invasive methods are seen as favorable by patients and are likely to result in an increase in compliance, thus improving glycaemia control and leading to a reduction in diabetic complications
What drug classes within the diabetes market are outperforming and underperforming the current market sales growth and why this is happening
Analysing diabetic neuropathy and the affects this has on the nerves throughout the Body- How new advancing formulations are lowing the blood glucose levels, so protecting the nerves throughout the body
What strategies are the leading companies implementing to protect off patent drugs and extend product lifecycles?
Specific country breakdown of the market and examine the major companies involved in the market, in terms of their products, sales and strategic measures
What could the future brings for stem cell therapies and how legislation is having effect on advancing scientific findings
Key Speakers
Dr Andrew G. Swick, Director, Cardiovascular & Metabolic Diseases, Pfi zer
Dr James Bainbridge, Consultant Ophthalmologist, Moorfi elds Eye Hospital
Peter Damsbo, Managing Director, Damsbo
Dr Yasser Abdel- Wahab, Senior Lecturer in Biomedical Sciences, University of Ulster
Daniel Crockett, Managing Editor, Diabetes.co.uk
Martin Walter, Partner, Simon-Kucher & Partners
Professor Michael Cawthrone, Professorial Research Fellow and Director of Metabolic Research, Clore Laboratory, University of Buckinghamshire
Professor David Heal, Director, RenaSci Consultancy
Donny Wong, Principal Analyst, Cardiovascular & Metabolic Disorders, Decision Resources
Dr Roger New, Chief Scientist, Diabetology
Dr Costanza Emanueli, Reader of Experimental Cardiovascular and Medicine, Bristol University
Professor David Dunger, Professor of Paediatrics, University of Cambridge
Who will be there?
Companies:
Pharmaceutical and Biotech
Academics Research Organisations
Regulatory Organisations
Trade Organisations
Healthcare Professionals
Hospitals
VP's, Directors, Heads and Management of:
Endocrinology & Metabolism
Cardiovascular & Metabolic Diseases
Diabetes & Obesity, Clinical R&D
New Antidiabetic Agents
Metabolic Disease Research
Advanced Diabetes Systems
Department of Metabolic Research
Chief Scientific Officer
New Products Global Marketing
Licensing and Partnering
Drug Discovery
Drug Development
Regulatory Affairs
Business Development
Principle Investigators
For more information kindly visit:
http://www.bharatbook.com/
